Primary cutaneous cryptococcosis: the importance of early diagnosis^☆☆

Abstract

The species of the Cryptococcus neoformans complex show different epidemiological patterns in the infection of immunosuppressed or immunocompetent individuals, and a common tropism peculiarity for the central nervous system. Primary cutaneous cryptococcosis is a rare clinical entity, with manifestations that are initially restricted to the skin through fungal inoculation, and the absence of systemic disease. The authors report in the present study the case of a 61-year-old immunocompetent man, with a rapidly evolving mucoid tumor on abrasions in contact with bird droppings on the forearm. The early identification of the polymorphic skin manifestations and treatment are crucial for the favorable prognosis of the infection, which can be life-threatening.

KEYWORDS
Cryptococcosis; Fungal diseases; Skin; Skin diseases

In cryptococcosis, a fungal infection caused by encapsulated yeasts, the species Cryptococcus neoformans var.grubii and C. neoformans var. neoformans are associated with immunocompromised or immunocompetent hosts, and areas of bird excrement grouping; whereas the species Cryptococcus gattii, relates to immunocompetent hosts and plant residues (Eucalyptus camaldulensis) from tropical and subtropical areas.^1–3

After yeast inhalation, pulmonary involvement associated with meningoencephalitis can occur in a significant number of cases, with cutaneous manifestations occurring in 10% to 15% of them, due to the hematogenous dissemination of the infection. Primary cutaneous cryptococcosis (PCC) is a rare entity, initially restricted to the skin, caused by direct fungal inoculation, with no signs of systemic disease.^1–4 The primary or secondary cutaneous condition is polymorphic (papules, purpura, vesicles/blisters, pustules, nodules, tumors, ulcerations, necrotizing panniculitis/cellulite, abscesses, acne-like lesions and molluscum contagiosum-like lesions), and can delay the diagnosis and lead to unfavorable outcomes.^1–7

The mortality, estimated at 10% in developed countries, can rise fourfold in countries such as Thailand. Although rare and with a favorable evolution, PCC can be life-threatening, particularly in patients with underlying diseases or immunocompromised patients, given the possibility of dissemination and central nervous system (CNS) involvement.^1–3,6

Case report

A 61-year-old male reported that 30 days before, a pruritic erythematous papule had appeared on his left forearm, which quickly progressed to a painful, friable and mucoid-like tumor (Fig. 1A). He had no fever, systemic complaints or lymph node enlargement, but the presence of excoriation on the forearms due to keeping and caring of birds. The PCC hypothesis and treatment with antifungal drugs were based on identification of yeast-like structures observed in the direct examination, that were later stained by Grocott-Gomori (Fig. 2A) and Mayer's mucicarmin stain (Fig. 2B) at the histopathological study, and identified by culture as Cryptococcus neoformans.

Figure 1
(A) Friable tumor with a mucoid aspect; (B) Post-detachment of the mucoid and necrotic plaque; (C) Healing at 120 days.

Figure 2
(A) Rounded structures with Grocott-Gomori silver methenamine staining; (B) and with Mayer's mucicarmine staining.

Serology study, including latex test for cryptococcosis and ELISA for HIV infection were negative; chest radiography and CSF analysis were normal. The treatment with intravenous fluconazole (400 mg daily), for 30 days, promoted the detachment of the mucoid and necrotic plaque (Fig. 1B), which was followed by oral use for 11 months with total re-epithelialization (Fig. 1C).

The PCC diagnosis criteria include the restriction to cutaneous manifestations with no evidence of systemic disease and positive culture for Cryptococcus spp.; and, additionally, single lesion or confined to one uncovered body area (limbs or face), previous traumas, abrasions, pre-existing skin ulcerations or lesions at the infection site and exposure to the contaminated source.^2,4

In the review of 11 cases of PCC in immunocompetent hosts, published in Brazil, older age was observed (mean of 70.91 years), as well as a predominance of male sex (81.82%), with previous trauma and/or exposure of the lesion site to contaminated sources (63.63%), and mean time of 62.14 days (15 to 210 days) until diagnosis. They shared forearm involvement, ulceration on plaques or nodules, shiny, mucoid or gelatinous nodules and/or tumors; pruritus at the start (three cases), pain and necrosis (two cases), cure for the majority of patients, but one death in a patient with cirrhosis and alcohol abuse.^4–10

The anatomical site and the host's immune status are the treatment-defining factors. For the management of less common manifestations in the HIV-negative population with a single infection site, with no evidence of CNS involvement, fungemia or immunosuppression, oral fluconazole (6 mg/kg/daily) for 6 to 12 months has been recommended.³

Considering that the cutaneous manifestation may precede the disseminated infection, its identification and early therapeutic interventions are crucial for reducing unfavorable outcomes.

• ☆☆
  Study conducted at the Division of Dermatology, Department of Internal Medicine, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
• Financial support
  None declared.

References

• ¹
  Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016;30:179-206.
• ²
  Christianson JC, Engber W, Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol. 2003;41:177-88.
• ³
  Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291-322.
• ⁴
  Marques SA, Bastazini I, Martins ALGP, Barreto JA, D’Elia MPB, Lastória JCL, et al. Primary cutaneous cryptococcosis in Brazil: report of 11 cases in immunocompetent and immunosuppressed patients. Int J Dermatol. 2012;51:780-4.
• ⁵
  Lacaz CS, Heins-Vaccari EM, Hernández-Arriagada GL, Martins EL, Prearo CAL, Corim SM, et al. Primary cutaneous cryptococcosis due to Cryptococcus neoformans var. gattii serotype B, in an immunocompetent patient. Rev Inst Med Trop Sao Paulo. 2002;44:225-8.
• ⁶
  França AVC, Carneiro M, dal Sasso K, Souza Silva C, Martinelli A. Cryptococcosis in cirrhotic patients. Mycoses. 2005;48:68-72.
• ⁷
  Leão CA, Ferreira-Paim K, Andrade-Silva L, Mora DJ, Silva PR, Machado AS, et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host. Med Mycol. 2011;49:352-5.
• ⁸
  Nasser N, Nasser Filho N, Vieira AG. Primay cutaneous cryptococcosis in an immunocompetent patient. An Bras Dermatol. 2011;86:1178-80.
• ⁹
  Pasa CR, Chang MR, Hans-Filho G. Post-trauma primary cutaneous cryptococcosis in an immunocompetent host by Cryptococcus gattii VGII. Mycoses. 2012;55:e1-3.
• ¹⁰
  Nascimento E, Silva Menb, Martinez R, von Zeska KMR. Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type VGI in Brazil: a case report and review of literature. Mycoses. 2014;57:442-7.

Publication Dates

• Publication in this collection
  02 Aug 2021
• Date of issue
  May-Jun 2021

History

• Received
  4 Oct 2020
• Accepted
  7 Dec 2020